Kiora Pharma receives EU orphan designation for KIO-301 in inherited retinal dystrophies

KIORA PHARMACEUTICALS INC

EMA grants Orphan Medicinal Product Designation for KIO-301 in non-syndromic rod-dominant retinal dystrophies including retinitis pigmentosa.
Provides at least 10 years of market exclusivity in Europe, reduced fees, centralized approval, and EMA scientific advice.
KIO-301 already has US Orphan Drug Designation; Phase 2 ABACUS-2 trial expected to initiate later in 2024.
KIO-301 is a small molecule photoswitch designed to restore light sensing in degenerated retinas, a non-gene therapy approach.
Co-development and commercialization partner Théa Open Innovation covers ex-Asia territories.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.